Skip to main content

Table 1 Study population characteristics

From: Identifying individuals with virologic failure after initiating effective antiretroviral therapy: The surprising value of mean corpuscular hemoglobin in a cross-sectional study

 

Training Data (n = 784)

Validation Data (n = 784)

Median Age (IQR)

42.4 (36.7, 47.6)

41.8 (36.2, 48.3)

Male Sex - N (%)

500 (64)

522 (67)

Race - N (%)

  

   African-American

588 (75)

589 (75)

   White

169 (22)

174 (22)

   Other

27 (3)

21 (3)

HIV Risk Behaviors - N (%)*

  

   MSM

203 (26)

203 (26)

   IDU

288 (37)

290 (37)

   Heterosexual

412 (53)

399 (51)

Median RNA (IQR) copies/ml**

155 (50, 6147)

145 (50, 7071)

Median CD4 (IQR) cells/ul**

273 (149, 441)

279 (133, 418)

 

[N = 701 (89%)]†

[N = 695 (89%)]†

Median Change in Percent CD4 (IQR)***

2.9 (0.0, 6.7)

3.0 (-0.4, 7.3)

 

[N = 655 (84%)]†

[N = 635 (81%)]†

Median MCH (IQR) (pg/cell)**

33.0 (30.2, 36.6)

32.8 (29.9, 36.2)

 

[N = 413 (53%)]†

[N = 410 (52%)]†

Median Change in MCH (IQR)***

1.7 (-0.2, 4.3)

1.8 (-0.3, 5.2)

 

[N = 364 (46%)]†

[N = 360 (46%)]†

  1. *HIV risk behaviors are reported behaviors at enrollment into the cohort and are not mutually exclusive
  2. ** At time of first HIV RNA measurement at least 4 months after initiation of effective therapy
  3. *** Change is the change from pre-HAART levels to marker measurement concurrent with HIV RNA measurement occurring at least 4 months after initiation of treatment.
  4. † The number and percent in brackets correspond to the number of individuals that were not missing these data.